{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:50:40Z","timestamp":1791654640931,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.josat.2026.210095","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:49:26Z","timestamp":1787701766000},"page":"210095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Adverse events reported to FDA Adverse Event Reporting System for long-acting injectable buprenorphine during the first 18\u00a0months postlaunch"],"prefix":"10.1016","volume":"191","author":[{"given":"Brian J.","family":"Dawson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie R.","family":"Budilovsky-Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Kaempfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.josat.2026.210095_bb0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13311-019-00814-4","article-title":"Availability of medications for the treatment of alcohol and opioid use disorder in the USA","volume":"17","author":"Abraham","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.josat.2026.210095_bb0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2105\/AJPH.2019.305366","article-title":"Opioid use fueling HIV transmission in an urban setting: An outbreak of HIV infection among people who inject drugs-Massachusetts, 2015-2018","volume":"110","author":"Alpren","year":"2020","journal-title":"American Journal of Public Health"},{"issue":"2S","key":"10.1016\/j.josat.2026.210095_bb0015","first-page":"1","article-title":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update","volume":"14","author":"American Society of Addiction Medicine","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2026.210095_bb0020","author":"Avalere Health"},{"issue":"4","key":"10.1016\/j.josat.2026.210095_bb0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/ADM.0000000000001430","article-title":"A naturalistic study of individuals involved in the justice system who experienced both formulations of extended-release buprenorphine","volume":"19","author":"Blue","year":"2025","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.josat.2026.210095_bb0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.9740\/mhc.2020.05.070","article-title":"Clozapine and hematologic adverse reactions: Impact of the risk evaluation and mitigation strategy program","volume":"10","author":"Borrelli","year":"2020","journal-title":"The Mental Health Clinician"},{"key":"10.1016\/j.josat.2026.210095_bb0035","series-title":"Brixadi\u00ae (buprenorphine) extended-release injection for subcutaneous use CIII","year":"2023"},{"key":"10.1016\/j.josat.2026.210095_bb0040","series-title":"Camurus announces US launch of Brixadi\u2122 for the treatment of moderate to severe opioid use disorder by Braeburn","author":"Camurus","year":"2023"},{"issue":"1","key":"10.1016\/j.josat.2026.210095_bb0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","article-title":"Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: An overview","volume":"35","author":"Correll","year":"2021","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.josat.2026.210095_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5968","article-title":"Untreated opioid use disorder and health-related quality of life among syringe service program clients","volume":"7","author":"Deaner","year":"2024","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.210095_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.josat.2026.210095_bb0060","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jpainsymman.2013.03.001","article-title":"Buprenorphine","volume":"45","author":"Foster","year":"2013","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1016\/j.josat.2026.210095_bb0065","series-title":"Drug overdose deaths in the United States, 2003\u20132023","author":"Garnett","year":"2024"},{"issue":"10173","key":"10.1016\/j.josat.2026.210095_bb0070","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.josat.2026.210095_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2024.100813","article-title":"Impact of opioid overdoses on US life expectancy and years of life lost, by demographic group and stimulant co-involvement: A mortality data analysis from 2019 to 2022","volume":"36","author":"H\u00e9bert","year":"2024","journal-title":"The Lancet Regional Health Americas"},{"key":"10.1016\/j.josat.2026.210095_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2023.100133","article-title":"History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder","volume":"6","author":"Heidbreder","year":"2023","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"10.1016\/j.josat.2026.210095_bb0085","author":"Indivior"},{"key":"10.1016\/j.josat.2026.210095_bb0090","author":"Indivior PLC"},{"key":"10.1016\/j.josat.2026.210095_bb0095","author":"Indivior PLC"},{"key":"10.1016\/j.josat.2026.210095_bb0100","author":"Indivior PLC"},{"key":"10.1016\/j.josat.2026.210095_bb0105","author":"Indivior PLC"},{"key":"10.1016\/j.josat.2026.210095_bb0110","author":"Indivior PLC"},{"key":"10.1016\/j.josat.2026.210095_bb0115","author":"Indivior PLC"},{"issue":"2","key":"10.1016\/j.josat.2026.210095_bb0120","first-page":"15","article-title":"FDA Adverse Event Reporting System (FAERS) database: A comprehensive analysis of its structure, functionality, and limitations","volume":"5","author":"Ismail","year":"2022","journal-title":"Sage Science Review of Applied Machine Learning"},{"key":"10.1016\/j.josat.2026.210095_bb0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jsat.2018.08.011","article-title":"Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management","volume":"94","author":"Kenney","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2026.210095_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the US?: A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"10.1016\/j.josat.2026.210095_bb0135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"21","key":"10.1016\/j.josat.2026.210095_bb0140","first-page":"1944","article-title":"A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database","volume":"248","author":"Le","year":"2023","journal-title":"Experimental Biology and Medicine (Maywood, N.J.)"},{"issue":"6","key":"10.1016\/j.josat.2026.210095_bb0145","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"12","key":"10.1016\/j.josat.2026.210095_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-088617","article-title":"Patient experience of opioid use disorder treatment medications: A systematic review of contemporary qualitative research","volume":"14","author":"Lowry","year":"2024","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.josat.2026.210095_bb0155","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.josat.2026.210095_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.josat.2026.210095_bb0165","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2026.210095_bb0170","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1016\/j.josat.2026.210095_bb0175","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega","year":"2023","journal-title":"The Lancet HIV"},{"issue":"1","key":"10.1016\/j.josat.2026.210095_bb0180","article-title":"The past, present and future of opioid withdrawal assessment: A scoping review of scales and technologies","volume":"19","author":"Nuamah","year":"2019","journal-title":"BMC Medical Informatics and Decision Making"},{"issue":"3","key":"10.1016\/j.josat.2026.210095_bb0185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA Adverse Event Reporting System (FAERS) essentials: A guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1016\/j.josat.2026.210095_bb0190","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","article-title":"Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: A retrospective analysis using the FDA Adverse Events Reporting System","volume":"40","author":"Silberstein","year":"2023","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.josat.2026.210095_bb0195","series-title":"Sublocade\u00ae (buprenorphine extended-release) injection, for subcutaneous use, CIII","year":"2025"},{"key":"10.1016\/j.josat.2026.210095_bb0200","series-title":"Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health","author":"Substance Abuse and Mental Health Services Administration","year":"2025"},{"issue":"1683","key":"10.1016\/j.josat.2026.210095_bb0205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.58347\/tml.2023.1683c","article-title":"Once-weekly or once-monthly subcutaneous buprenorphine (Brixadi) for opioid use disorders","volume":"65","year":"2023","journal-title":"The Medical Letter on Drugs and Therapeutics"},{"key":"10.1016\/j.josat.2026.210095_bb0210","unstructured":"US Centers for Disease Control and Prevention. (14 May 2025). US overdose deaths decrease almost 27% in 2024. Retrieved 9 October 2025 from https:\/\/www.cdc.gov\/nchs\/pressroom\/releases\/20250514.html."},{"key":"10.1016\/j.josat.2026.210095_bb0215","author":"US Food and Drug Administration"},{"issue":"2","key":"10.1016\/j.josat.2026.210095_bb0220","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.210095_bb0225","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796025100085","article-title":"Global, regional, and national trends and burden of opioid use disorder in individuals aged 15 years and above: 1990 to 2021 and projections to 2040","volume":"34","author":"Wang","year":"2025","journal-title":"Epidemiology and Psychiatric Sciences"},{"issue":"6","key":"10.1016\/j.josat.2026.210095_bb0230","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1037\/pha0000654","article-title":"Clinically meaningful individual differences in opioid withdrawal expression","volume":"31","author":"Ware","year":"2023","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"3","key":"10.1016\/j.josat.2026.210095_bb0235","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0558","article-title":"Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use","volume":"1","author":"Winkelman","year":"2018","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2026.210095_bb0240","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Scientific Reports"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926002158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926002158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:34:49Z","timestamp":1791653689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875926002158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":48,"alternative-id":["S2949875926002158"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2026.210095","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events reported to FDA Adverse Event Reporting System for long-acting injectable buprenorphine during the first 18\u00a0months postlaunch","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2026.210095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"210095"}}